Bovine Vaccines

Bovine Vaccines Market Outlook

The global bovine vaccines market is projected to reach approximately USD 8.5 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period from 2025 to 2035. This significant growth can be attributed to the increasing prevalence of bovine diseases, rising awareness among farmers regarding animal health and welfare, and advancements in vaccine technology. Moreover, the growing demand for meat and dairy products in developing countries drives the need for effective vaccination strategies to enhance livestock productivity and prevent disease outbreaks. Additionally, the focus on sustainable practices in agriculture is leading to increased investments in vaccine research and development, further propelling market growth.

Growth Factor of the Market

One of the primary growth factors in the bovine vaccines market is the rising incidence of infectious diseases among cattle, which necessitates the use of vaccines to safeguard the health of herds. Diseases such as Foot and Mouth Disease (FMD) and Bovine Respiratory Disease (BRD) not only affect animal welfare but also result in substantial economic losses for farmers due to reduced productivity and increased veterinary costs. Additionally, the shift towards intensive livestock farming practices has intensified the need for vaccination to maintain herd immunity and prevent disease transmission. The increasing adoption of biosecurity measures and veterinary health programs among livestock farmers is also a significant driver for the bovine vaccines market. Furthermore, government initiatives and regulations aimed at controlling and eradicating livestock diseases have led to increased funding for vaccine development and distribution, further boosting market growth.

Key Highlights of the Market

• The bovine vaccines market is expected to witness a steady growth rate fueled by technological advancements in vaccine production.
• Inactivated vaccines are expected to dominate the product type segment due to their long-lasting immunity.
• Foot and Mouth Disease is projected to be the leading application area, driven by its high prevalence and economic impact on the livestock industry.
• Veterinary clinics are anticipated to be the primary distribution channel for bovine vaccines, ensuring direct access to farmers.
• Geographically, North America holds a significant market share, attributed to advanced veterinary healthcare infrastructure and high livestock populations.

By Product Type

Inactivated Vaccines:

Inactivated vaccines are one of the most widely used types in bovine vaccination programs. These vaccines are created by killing the pathogens that cause the disease, which helps in eliciting an immune response without causing the actual disease. They are preferred due to their safety profile and stability, making them easier to store and transport compared to live vaccines. The effectiveness of inactivated vaccines in providing long-term immunity against diseases such as Foot and Mouth Disease and Bovine Viral Diarrhea has further solidified their role in veterinary immunization strategies. As a result, the market for inactivated vaccines is expected to witness significant growth as farmers prioritize herd health and productivity.

Live Attenuated Vaccines:

Live attenuated vaccines are made from live pathogens that have been weakened or attenuated so that they do not cause disease in healthy animals. These vaccines are known for their ability to induce a strong and long-lasting immune response, often requiring fewer doses for effective immunity. They are particularly beneficial for controlling outbreaks of diseases that can spread rapidly within cattle populations. However, the use of live vaccines requires careful handling to avoid reversion to virulence. As the demand for more effective vaccines increases, live attenuated vaccines are likely to see a steady rise in adoption among cattle farmers.

Recombinant Vaccines:

Recombinant vaccines represent a breakthrough in vaccine technology, utilizing genetic engineering to create vaccines that can provoke an immune response without utilizing live pathogens. This type of vaccine can be designed to target specific antigens, providing a tailored approach to disease prevention in cattle. The versatility and efficacy of recombinant vaccines make them a favorable option, particularly for diseases with complex pathogen profiles. As research in genetic engineering continues to advance, the market for recombinant bovine vaccines is expected to grow significantly, offering innovative solutions for livestock health management.

DNA Vaccines:

DNA vaccines are an emerging technology in the bovine vaccines market, where a plasmid containing the DNA sequence of specific antigens is introduced into the animal. This method stimulates the immune system to produce the necessary antibodies against pathogens. DNA vaccines are advantageous as they offer stability, can be produced quickly, and do not require adjuvants to enhance their efficacy. While still in the early stages of commercialization, the potential of DNA vaccines for bovine health is immense, and ongoing research may soon lead to their widespread adoption in veterinary practice.

Subunit Vaccines:

Subunit vaccines consist of purified pieces of the pathogen, such as proteins or sugars, which provoke an immune response without using whole pathogens. These vaccines have a favorable safety profile and a lower risk of causing adverse reactions in vaccinated animals. Subunit vaccines are particularly effective for diseases like Brucellosis and Clostridial infections, making them a critical component of bovine vaccination programs. The increasing focus on animal health and welfare is likely to drive the demand for subunit vaccines, as they provide an effective means of preventing diseases while minimizing risks associated with other vaccine types.

By Application

Foot and Mouth Disease:

Foot and Mouth Disease (FMD) remains one of the most critical challenges in cattle health globally, leading to severe economic losses in the livestock sector. FMD is highly contagious and can spread rapidly among cattle populations, necessitating prompt vaccination to prevent outbreaks. Vaccines developed for FMD are crucial in controlling the disease, reducing the incidence of infection, and enabling the safe movement of livestock. With increasing investments in veterinary services and vaccination programs aimed at disease eradication, the FMD application segment is expected to dominate the bovine vaccines market significantly.

Bovine Viral Diarrhea:

Bovine Viral Diarrhea (BVD) is another prevalent disease affecting cattle, characterized by severe diarrhea, immune suppression, and reproductive issues. Vaccines targeting BVD are essential for maintaining herd health and productivity, especially in dairy herds where transmission can lead to substantial economic losses. The focus on herd immunity and biosecurity measures has driven the demand for effective BVD vaccines as part of comprehensive herd health management practices. As awareness among farmers regarding the ramifications of BVD increases, the market for vaccines addressing this disease is expected to see substantial growth.

Bovine Respiratory Disease:

Bovine Respiratory Disease (BRD) is a complex syndrome affecting cattle, often resulting from multiple pathogens and environmental stressors. Vaccination plays a pivotal role in controlling BRD, as it helps to reduce the incidence and severity of the disease. Effective vaccines can enhance immune responses and improve overall herd health, reducing treatment costs associated with BRD outbreaks. The increasing prevalence of respiratory diseases in cattle, coupled with the growing focus on animal welfare, supports the expansion of the market for BRD vaccines, making them a critical component of vaccination strategies.

Clostridial Diseases:

Clostridial diseases, caused by various bacterial pathogens, pose significant health risks to cattle, leading to sudden deaths and economic losses for farmers. Vaccines developed to prevent clostridial infections are crucial in ensuring herd health, and they are often part of routine vaccination protocols in cattle management. The rising awareness of the impact of clostridial diseases on livestock productivity and profitability drives the demand for effective clostridial vaccines. As vaccination becomes an integral part of herd management, the market for clostridial disease vaccines is poised for growth.

Brucellosis:

Brucellosis is a contagious disease affecting cattle, leading to reproductive issues and reduced milk production. The economic implications of this disease highlight the importance of vaccination in preventing its spread. Vaccination against Brucellosis is not only a means of protecting the health of the cattle but also an essential component of food safety and public health. The increasing regulatory focus on eradicating Brucellosis in cattle populations is expected to drive the growth of the market for vaccines targeting this disease, as governments and farmers alike prioritize effective vaccination strategies.

By Distribution Channel

Veterinary Clinics:

Veterinary clinics are a primary distribution channel for bovine vaccines, providing direct access to farmers and livestock owners for vaccination services. These clinics play a crucial role in the education of farmers regarding vaccination schedules, disease prevention, and overall herd management. The convenience of obtaining vaccines from local veterinary clinics encourages farmers to adhere to vaccination protocols, ensuring that cattle are protected against prevalent diseases. As veterinary clinics continue to expand their services and enhance their outreach to farmers, their role in the distribution of bovine vaccines will remain significant.

Veterinary Hospitals:

Veterinary hospitals also serve as important distribution points for bovine vaccines, often offering a wider range of services, including diagnostics and treatment for various health conditions. These hospitals are equipped with trained professionals who can assess the health status of cattle and recommend appropriate vaccination programs. The integration of vaccination services within veterinary hospitals helps streamline the process for farmers, allowing for comprehensive healthcare solutions for their livestock. As the demand for advanced veterinary services increases, veterinary hospitals are expected to play a larger role in the distribution of bovine vaccines.

Veterinary Research Institutes:

Veterinary research institutes contribute to the distribution and development of bovine vaccines by conducting vital research and trials to ensure vaccine efficacy and safety. These institutions play an essential role in advancing vaccine technology and developing new formulations to address emerging diseases in cattle. By collaborating with agricultural stakeholders, these research institutes help disseminate knowledge regarding vaccine development and distribution channels, promoting best practices in cattle vaccination. Their ongoing research initiatives are critical in shaping the future of bovine vaccination strategies.

Online Pharmacies:

Online pharmacies are becoming an increasingly popular distribution channel for bovine vaccines, allowing farmers to access vaccines conveniently and efficiently. The rise of e-commerce has transformed the way veterinary products are distributed, providing farmers with the option to order vaccines from the comfort of their homes. This accessibility is particularly beneficial for remote or rural areas where traditional veterinary services may be limited. As the trend toward online shopping continues to gain momentum, online pharmacies are expected to capture a larger share of the bovine vaccines market, enhancing the overall reach and availability of vaccination solutions.

By Ingredient Type

Brucella abortus:

Brucella abortus is a significant pathogen that causes Brucellosis in cattle, leading to reproductive losses and economic impacts on the livestock industry. Vaccines containing Brucella abortus antigens are critical for preventing this disease and ensuring herd health. The use of Brucella abortus in vaccines has been instrumental in controlling the spread of Brucellosis, and ongoing research continues to optimize these vaccines for improved efficacy and safety. As regulations surrounding Brucellosis management become stricter, the demand for vaccines based on Brucella abortus is expected to rise.

Mannheimia haemolytica:

Mannheimia haemolytica is a major bacterial pathogen associated with Bovine Respiratory Disease, leading to significant health issues in cattle. Vaccines targeting Mannheimia haemolytica are essential for controlling respiratory infections and reducing the impact of BRD outbreaks. The increasing prevalence of respiratory diseases in cattle populations highlights the importance of effective vaccination strategies, and the demand for Mannheimia haemolytica-based vaccines is likely to grow in response to this challenge.

Bovine Rotavirus:

Bovine Rotavirus is a viral pathogen responsible for calf diarrhea, which can result in high mortality and economic losses for cattle producers. Vaccination against Bovine Rotavirus is crucial in preventing outbreaks and ensuring the health of young calves. The market for vaccines targeting Bovine Rotavirus is expected to expand as farmers become more aware of the benefits of vaccination in maintaining calf health and productivity. As research continues to develop more effective vaccines, the impact of Bovine Rotavirus vaccines will become increasingly significant in herd management practices.

Bovine Coronavirus:

Bovine Coronavirus is another viral agent that contributes to gastrointestinal diseases in cattle, particularly in young calves. Vaccines designed to target Bovine Coronavirus are critical in preventing these infections and ensuring the health of livestock. The rising incidence of viral infections in cattle populations underscores the importance of effective vaccination strategies. As the cattle industry focuses on enhancing biosecurity measures and disease prevention, the demand for vaccines against Bovine Coronavirus is expected to increase significantly.

Mycobacterium bovis:

Mycobacterium bovis is the causative agent of bovine tuberculosis, a significant zoonotic disease that poses a threat to both animal and human health. Vaccination against Mycobacterium bovis is essential in controlling the spread of bovine tuberculosis, particularly in regions where the disease is prevalent. The development of effective vaccines targeting this pathogen is critical for ensuring herd health and safeguarding public health. As awareness of the impacts of bovine tuberculosis grows, the market for Mycobacterium bovis vaccines is expected to expand, driven by the need for effective disease management strategies.

By Region

North America holds a prominent share of the bovine vaccines market, driven by its advanced veterinary healthcare infrastructure and high livestock populations. The United States, in particular, has made significant investments in vaccination programs aimed at controlling diseases like Foot and Mouth Disease and Bovine Viral Diarrhea. The region is expected to experience a steady CAGR of 5.5% during the forecast period, bolstered by increasing awareness of animal health and welfare among farmers. Furthermore, government initiatives to promote biosecurity and vaccination practices are expected to support market growth in North America.

In Europe, the bovine vaccines market is also witnessing robust growth, attributed to stringent regulations regarding animal health and welfare. The European Union has implemented policies aimed at eradicating certain livestock diseases, resulting in increased demand for effective vaccines. Countries such as Germany, France, and the United Kingdom are at the forefront of vaccine development, focusing on innovative solutions to combat diseases affecting cattle. The growing trend towards sustainable livestock farming and the emphasis on disease prevention are likely to drive significant growth in the European bovine vaccines market over the coming years.

Opportunities

The bovine vaccines market presents numerous opportunities for stakeholders, particularly in the realm of research and development. Innovations in vaccine technology, including the development of genetically engineered and recombinant vaccines, hold the potential to enhance efficacy and safety profiles, addressing the limitations of traditional vaccines. As consumer demand for safe and sustainable animal products rises, there is an increasing push for vaccines that can reduce antibiotic usage in livestock management. Companies that invest in R&D to develop next-generation vaccines are likely to benefit from an expanding market, as they can offer farmers cutting-edge solutions to improve animal health and productivity.

Moreover, the global trend towards greater awareness of animal welfare and improved biosecurity measures presents significant opportunities for the bovine vaccines market. As farmers become more informed about the benefits of vaccination in preventing disease outbreaks, there is a growing inclination to adopt comprehensive vaccination protocols. This shift towards proactive health management strategies is expected to drive demand for bovine vaccines, creating opportunities for manufacturers and distributors to expand their offerings and reach new markets. Collaborative efforts between governments, research institutions, and private companies can further enhance these opportunities, leading to more effective vaccination programs for cattle worldwide.

Threats

Despite the growth potential in the bovine vaccines market, there are several threats that could hinder market expansion. One of the primary threats is the emergence of vaccine-resistant strains of pathogens, which can compromise the effectiveness of existing vaccines. As livestock diseases evolve, there is a risk that traditional vaccination strategies may not provide adequate protection, leading to increased disease prevalence and economic losses for cattle producers. Additionally, the rising costs associated with vaccine development and production could limit access to effective vaccination solutions, particularly in developing regions where resources are constrained. These challenges necessitate continuous monitoring and innovation within the bovine vaccines market to ensure that farmers have access to reliable and effective vaccination options.

Another significant concern within the bovine vaccines market is the regulatory environment surrounding vaccine approvals and use. Stringent regulations can delay the introduction of new vaccines and complicate existing vaccination programs. The complexity of navigating these regulatory frameworks can deter smaller companies from entering the market, limiting competition and stifling innovation. Furthermore, public perceptions surrounding vaccine safety and efficacy can pose challenges to widespread adoption. Misinformation and skepticism regarding vaccines can impact vaccination rates among cattle, undermining efforts to control livestock diseases and protect herd health. Addressing these threats will require collaborative efforts among stakeholders in the veterinary and agricultural sectors.

Competitor Outlook

• Zoetis
• Merck Animal Health
• Elanco Animal Health
• Boehringer Ingelheim
• Ceva Animal Health
• Virbac
• Heska Corporation
• Vetoquinol
• HIPRA
• Phibro Animal Health
• Ovation Pharmaceuticals
• Neogen Corporation
• AgriLabs
• Intervet International
• KPPM Animal Health

The competitive landscape of the bovine vaccines market is characterized by the presence of several key players and a collaborative approach to innovation and distribution. Major companies such as Zoetis and Merck Animal Health lead the market with their extensive portfolios of vaccines and a strong focus on research and development. These companies are actively involved in the introduction of new vaccine formulations and technologies, ensuring they remain at the forefront of advancements in bovine health management. Their strategic partnerships with veterinary clinics and research institutes facilitate the dissemination of knowledge regarding vaccination protocols and best practices, thereby enhancing market penetration.

In addition to established players, smaller companies are also emerging in the bovine vaccines market, contributing to the competitive landscape with innovative products. These companies often focus on niche segments or specialized vaccines targeting specific diseases, allowing them to carve out a unique market presence. The increasing demand for effective vaccination solutions is prompting collaboration between larger corporations and smaller firms, resulting in a mutually beneficial exchange of expertise and resources. This dynamic fosters an environment of innovation and ensures that farmers have access to a diverse range of vaccine options tailored to their specific needs.

Regional players also play a critical role in the competition within the bovine vaccines market. Companies based in Europe, North America, and Asia Pacific are leveraging their local knowledge and understanding of market dynamics to develop tailored solutions for farmers in their regions. These players often emphasize sustainable practices and animal welfare in their product offerings, aligning with the growing trend towards ethical livestock farming. As the market evolves, it is expected that competition will intensify, leading to further advancements in vaccine technology and distribution strategies, ultimately benefiting the global livestock industry.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 HIPRA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Virbac
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Zoetis
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AgriLabs
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Vetoquinol
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Heska Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Ceva Animal Health
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 KPPM Animal Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Neogen Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck Animal Health
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Elanco Animal Health
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Phibro Animal Health
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Intervet International
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Ovation Pharmaceuticals
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Bovine Vaccines Market, By Application
    • 6.1.1 Foot and Mouth Disease
    • 6.1.2 Bovine Viral Diarrhea
    • 6.1.3 Bovine Respiratory Disease
    • 6.1.4 Clostridial Diseases
    • 6.1.5 Brucellosis
  • 6.2 Bovine Vaccines Market, By Product Type
    • 6.2.1 Inactivated Vaccines
    • 6.2.2 Live Attenuated Vaccines
    • 6.2.3 Recombinant Vaccines
    • 6.2.4 DNA Vaccines
    • 6.2.5 Subunit Vaccines
  • 6.3 Bovine Vaccines Market, By Ingredient Type
    • 6.3.1 Brucella abortus
    • 6.3.2 Mannheimia haemolytica
    • 6.3.3 Bovine Rotavirus
    • 6.3.4 Bovine Coronavirus
    • 6.3.5 Mycobacterium bovis
  • 6.4 Bovine Vaccines Market, By Distribution Channel
    • 6.4.1 Veterinary Clinics
    • 6.4.2 Veterinary Hospitals
    • 6.4.3 Veterinary Research Institutes
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Bovine Vaccines Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Bovine Vaccines market is categorized based on

By Product Type

• Inactivated Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• DNA Vaccines
• Subunit Vaccines

By Application

• Foot and Mouth Disease
• Bovine Viral Diarrhea
• Bovine Respiratory Disease
• Clostridial Diseases
• Brucellosis

By Distribution Channel

• Veterinary Clinics
• Veterinary Hospitals
• Veterinary Research Institutes
• Online Pharmacies

By Ingredient Type

• Brucella abortus
• Mannheimia haemolytica
• Bovine Rotavirus
• Bovine Coronavirus
• Mycobacterium bovis

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Zoetis
• Merck Animal Health
• Elanco Animal Health
• Boehringer Ingelheim
• Ceva Animal Health
• Virbac
• Heska Corporation
• Vetoquinol
• HIPRA
• Phibro Animal Health
• Ovation Pharmaceuticals
• Neogen Corporation
• AgriLabs
• Intervet International
• KPPM Animal Health